Review
Cardiac & Cardiovascular Systems
Thomas D. Bernier, Leo F. Buckley
Summary: Left ventricular systolic dysfunction is a common issue in heart failure patients that requires new safe and effective therapies for improvement, as current medications have limited efficacy. Recent studies have identified two novel cardiac myotropes that target cardiac myosin to enhance left ventricular systolic function, but further evaluation of their clinical efficacy and safety is needed.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Mikael Erhardsson, Ulrika L. Faxen, Ashwin Venkateshvaran, Camilla Hage, Gianluigi Pironti, Tonje Thorvaldsen, Dominic-Luc Webb, Per M. Hellstroem, Daniel C. Andersson, Marcus Stahlberg, Lars H. Lund
Summary: Acyl ghrelin therapy in heart failure patients with reduced ejection fraction can increase cardiac output while preserving or improving right ventricular-pulmonary arterial coupling. This may be due to increased contractility, reduced pulmonary vascular resistance, and/or reduced left-sided filling pressures.
Article
Cardiac & Cardiovascular Systems
Scott D. Solomon, Brian L. Claggett, Zi Michael Miao, Rafael Diaz, G. Michael Felker, John J. McMurray, Marco Metra, Ramon Corbalan, Gerasimos Filippatos, Assen R. Goudev, Viatcheslav Mareev, Pranas Serpytis, Thomas Suter, Mehmet B. Yilmaz, Faiez Zannad, Stuart Kupfer, Stephen B. Heitner, Fady Malik, John R. Teerlink
Summary: In the GALACTIC-HF study, the influence of atrial fibrillation on the effectiveness of omecamtiv mecarbil was explored. The study found that patients with atrial fibrillation derived less benefit from omecamtiv mecarbil treatment, especially those who were also receiving digoxin.
EUROPEAN HEART JOURNAL
(2022)
Review
Cardiac & Cardiovascular Systems
Brian P. Halliday, Roxy Senior, Dudley J. Pennell
Summary: The measurement of left ventricular ejection fraction (LVEF) has been a key component in imaging studies for cardiac patients, but its utility as a prognostic indicator has diminished in certain populations such as heart failure patients with preserved ejection fraction (HF-PEF) and those with valvular heart disease. Assessing myocardial strain, particularly global longitudinal strain (GLS), holds promise in improving risk stratification and therapy selection for these patients. Additional studies are needed to fully integrate GLS into routine clinical practice and improve patient outcomes.
EUROPEAN HEART JOURNAL
(2021)
Review
Cardiac & Cardiovascular Systems
Brian P. Halliday, Roxy Senior, Dudley J. Pennell
Summary: Traditional methods of assessing cardiac function like LVEF are no longer accurate in predicting prognosis for heart failure patients, highlighting the need for better indicators such as GLS to improve risk stratification and accuracy of disease assessment. For patients with heart failure and valvular heart disease, GLS may be a superior option to consider.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Renato A. Hortegal, Renata Valeri, Mariana Grizante, Renato Cancellier, Carlos Gun, Jorge Assef, Henrique Moriya, Romeu Meneghelo, Fausto Feres, Kleber G. Franchini
Summary: The study aimed to improve the low sensitivity of HFpEF detection through provocative maneuvers. The findings revealed a significant decrease in peak strain during acute pressure overload in patients with HFpEF.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Joshua Saef, Trejeeve Martyn, Anusha Ray Dey, Rola Khedraki, Lauren Ives, Patrick Collier, Wael A. Jaber, Jerry D. Estep, Mazen Hanna, Wai Hong Wilson Tang
Summary: This study reveals that in patients with impaired left ventricular ejection fraction (LVEF) due to ATTR-CM, more than one-third of patients showed improvement in LVEF over time, while those with a decrease in LVEF had worse long-term outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Arnold Peter Raduly, Fruzsina Sarkany, Mate Balazs Kovacs, Brigitta Bernat, Bela Juhasz, Zoltan Szilvassy, Robert Porszasz, Balazs Horvath, Norbert Szentandrassy, Peter Nanasi, Zoltan Csanadi, Istvan Edes, Attila Toth, Zoltan Papp, Daniel Priksz, Attila Borbely
Summary: Recent cardiotropic drug developments have focused on cardiac myofilaments, and danicamtiv, as the second direct myosin activator, has shown promising results in the treatment of heart failure with reduced ejection fraction. In vitro and in vivo studies have demonstrated that danicamtiv improves systolic function but may also limit diastolic performance at higher concentrations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cardiac & Cardiovascular Systems
Akito Nakagawa, Yoshio Yasumura, Chikako Yoshida, Takahiro Okumura, Jun Tateishi, Junichi Yoshida, Shunsuke Tamaki, Masamichi Yano, Takaharu Hayashi, Yusuke Nakagawa, Takahisa Yamada, Daisaku Nakatani, Shungo Hikoso, Yasushi Sakata
Summary: The study found that patients with preserved admission SBP had a higher risk for adverse outcomes of cardiac death and heart failure re-hospitalization in HFpEF. Compared to patients with elevated admission SBP, those with preserved SBP had a higher risk of poor prognosis.
Article
Cardiac & Cardiovascular Systems
Barry A. Borlaug, Yogesh N. V. Reddy, Amanda Braun, Hidemi Sorimachi, Massar Omar, Dejana Popovic, Alessio Alogna, Michael D. Jensen, Rickey Carter
Summary: This study found that treatment with dapagliflozin can reduce pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF, and has favorable effects on plasma volume and body weight.
Article
Medicine, Research & Experimental
Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta
Summary: OM, a novel cardiac myosin activator, is a weak inhibitor of BCRP substrates, as observed in a clinical study of single dose OM.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2021)
Article
Cardiac & Cardiovascular Systems
Tatsuro Hitsumoto, Osamu Tsukamoto, Ken Matsuoka, Junjun Li, Li Liu, Yuki Kuramoto, Shuichiro Higo, Shou Ogawa, Noboru Fujino, Shohei Yoshida, Hidetaka Kioka, Hisakazu Kato, Hideyuki Hakui, Yuki Saito, Chisato Okamoto, Hijiri Inoue, Jo Hyejin, Kyoko Ueda, Takatsugu Segawa, Shunsuke Nishimura, Yoshihiro Asano, Hiroshi Asanuma, Akiyoshi Tani, Riyo Imamura, Shinsuke Komagawa, Toshio Kanai, Masayuki Takamura, Yasushi Sakata, Masafumi Kitakaze, Jun-ichi Haruta, Seiji Takashima
Summary: This study demonstrates that dysregulation of cMLCK contributes to the development of cardiac systolic dysfunction in humans, and restoring cMLCK activity could serve as a novel myotropic therapy for advanced systolic heart failure.
Review
Cardiac & Cardiovascular Systems
Clement Lau, Mohamed M. M. Elshibly, Prathap Kanagala, Jeffrey P. Khoo, Jayanth Ranjit Arnold, Sandeep Singh Hothi
Summary: Heart failure is a major global cause of morbidity and mortality. Current classifications of heart failure categorize patients based on their left ventricular ejection fraction. Echocardiography is commonly used for assessing diastolic function, but cardiac magnetic resonance has emerged as a valuable tool for diagnosing and phenotype HFpEF. Cardiac magnetic resonance provides additional information and has diagnostic utility in differentiating acquired and inherited heart muscle diseases presenting as HFpEF. It is also used in clinical trials for assessing novel therapies in HFpEF.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Alia S. Alhakak, Morten Sengelov, Peter G. Jorgensen, Niels E. Bruun, Cecilie Johnsen, Ulrik Abildgaard, Allan Z. Iversen, Thomas F. Hansen, John R. Teerlink, Fady I. Malik, Scott D. Solomon, Gunnar Gislason, Tor Biering-Sorensen
Summary: In patients with HFrEF, SET provides independent and incremental prognostic information regarding all-cause mortality. MPI is a significant predictor in an unadjusted model, but the association does not remain significant after multivariable adjustment. No significant associations between IVCT or IVRT and mortality were found.
EUROPEAN JOURNAL OF HEART FAILURE
(2021)
Article
Physiology
Zabed Mahmud, Svetlana Tikunova, Natalya Belevych, Cory S. Wagg, Pavel Zhabyeyev, Philip B. Liu, David V. Rasicci, Christopher M. Yengo, Gavin Y. Oudit, Gary D. Lopaschuk, Peter J. Reiser, Jonathan P. Davis, Peter M. Hwang
Summary: Researchers have developed a small molecule, RPI-194, that can enhance cardiac muscle contraction and potentially be used to treat systolic heart failure.
FRONTIERS IN PHYSIOLOGY
(2022)